54
Participants
Start Date
April 15, 2025
Primary Completion Date
January 31, 2029
Study Completion Date
January 31, 2032
Nivolumab
40 mg day 1 and 15
Doxorubicin
25 mg/m2 day 1 and 15
Vinblastine
6 mg/m2 (not exceeding 10 mg) day 1 and 15
Dacarbazine
375 mg/m2 day 1 and 15
RECRUITING
"P. Hertsen Moscow Oncology Research Institute (MORI) for administrative and economic work - the branch of the FSBI National Medical Research Radiological Centre (NMRRC) of the Ministry of Health of the Russian Federation", Moscow
National Medical Research Radiological Centre of the Ministry of Health of Russia
OTHER